Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Also during the quarter, we initiated a position in Haemonetics Corporation (HAE), a developer and distributor of a broad portfolio of hematology products and solutions. The company operates...
— John W. Rogers, Jr.
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Haemonetics Corporation
Haemonetics Corporation ($HAE), constituting 2.7% of the fund, develops and distributes specialized hematology technologies, blood management products, and plasma collection solutions. The manager is...
Haemonetics designs and manufactures medical devices and consumable equipment dedicated to blood processing, plasma collection, and surgical suite hematology management. The manager is...
Haemonetics ($HAE) provides automated plasma collection systems, blood processing hardware, and specialized surgical interventional technologies. The manager's bullish...
More institutional theses from Ariel Fund
Zebra Technologies ($ZBRA) manufactures enterprise barcode scanners, mobile computing devices, and RFID tracking solutions that automate enterprise workflows, representing 5.0% of the portfolio. The manager maintains...
Charles River Laboratories ($CRL) provides essential preclinical laboratory testing, animal models, and drug discovery research services to biotechnology and pharmaceutical firms, accounting for 4.6% of fund assets. The manager maintains...
Midera Food Processing, Inc. ($MFP) represents 0.0% of the fund's portfolio following a complete post-spinoff liquidation to redeploy capital into higher-conviction names.